Inventaire - i tuoi amici e le tue comunità sono la tua biblioteca

Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog

autore

Alan D. Cherrington

Mary E. Courtney Moore

Tiffany D. Farmer

Marta S. Smith

pubblicato in: American Journal of Physiology - Endocrinology and Metabolism

data di pubblicazione: 2013-10-22

argomento principale: glucosio

Cita articoli 61

Data

Titolo

Autori

2013-05-22

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Julio Rosenstock, John E. Gerich
2013-04-29

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Michel Marre, Julio Rosenstock
2013-04-05

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Julio Rosenstock
2013-03-27

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

Bo Ahrén
2013-02-13

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

Karen L. Jones
2013-05-09

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

Martin Lorenz
2013-05-26

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
2013-04-18

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

Simon Veedfald, Carolyn F. Deacon, Bolette Hartmann, Filip K Knop, Jens Juul Holst, Astrid Plamboeck, André Wettergren, Søren Meisner, Claus Hovendal, Tina Vilsbøll
2012-11-27

Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study

Julio Rosenstock, Richard M Bergenstal
2012-05-30

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
2012-03-19

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

John E. Gerich
2012-04-05

Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans

Changting Xiao
2011-09-08

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
2011-03-11

Lixisenatide for type 2 diabetes mellitus

Tina Vilsbøll, Mikkel Christensen, Jens Juul Holst, Filip K Knop
2011-07-20

A high-fat, high-fructose diet accelerates nutrient absorption and impairs net hepatic glucose uptake in response to a mixed meal in partially pancreatectomized dogs

Alan D. Cherrington, Marta S. Smith, Doss W. Neal
2010-11-02

Glycation and biomarkers of vascular complications of diabetes
2010-09-01

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
2010-06-02

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
2010-06-08

GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet

Hanno Pijl
2010-11-03

Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying
2009-08-01

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

Jens Juul Holst
2009-02-06

GLP-1 regulates gastroduodenal motility involving cholinergic pathways
2008-05-16

Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake

Randy J. Seeley, Stephen C. Woods
2008-10-10

CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice

Vedrana Stojanovic-Susulic, Louis M Havekes, Hanno Pijl
2007-05

Biology of incretins: GLP-1 and GIP
2007-10-30

Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans
2007-10-18

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Jens Juul Holst, Mona Landin-Olsson, Carolyn F. Deacon, Julio Rosenstock
2007-10-01

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Jens Juul Holst, Steven E. Kahn, Carolyn F. Deacon, Santica M Marcovina
2007-02-15

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Michael Camilleri
2007-07-10

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
2007-10-01

Gastric emptying: a comparison of three methods

Henning Glerup, Jens F. Dahlerup
2006-06-01

Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs.

Jens Juul Holst, Cathrine Ørskov

Articolo - wd:Q37439806

Benvenuto su Inventaire

la biblioteca dei tuoi amici e della tua comunità

ulteriori informazioni